Prolato Research LLC

1. Sanofi US Services Inc. $827,639 80 payments
2. Pfizer Inc. $716,427 77 payments
3. Novartis Pharmaceuticals Corporation $504,634 22 payments
4. AstraZeneca UK Limited $388,718 4 payments
5. Otsuka Pharmaceutical Development & Commercialization, Inc. $335,554 9 payments
6. AstraZeneca Pharmaceuticals LP $230,438 10 payments
7. Retrophin, Inc. $200,722 399 payments
8. Hoffmann-La Roche Limited $146,728 77 payments
9. Amgen Inc. $115,677 4 payments
10. Alexion Pharmaceuticals, Inc. $65,018 5 payments

1. A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment $334,386 3 payments
2. A Phase 1 Randomized Study to Evaluate the Safety Tolerability and Immunogenicity of Combined Modified Rna Vaccine Candidates Against Covid19 and Influenza in Healthy Individuals $291,430 23 payments
3. A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis $221,310 12 payments
4. A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $215,338 21 payments
5. A Phase 12 Randomized Study to Evaluate the Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza in Healthy Individuals $187,589 22 payments
6. Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study $163,100 18 payments
7. A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis $162,436 12 payments
8. A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects With Immunoglobulin A Nephropathy $147,591 3 payments
9. Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients with Active Proliferative Lupus Nephritis $125,050 2 payments
10. A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis $117,620 7 payments

1. Other $180,026 369 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.